Brightspring Health Services, Inc. · NASDAQ:BTSG
Brightspring Health Services — Q4 2024 Earnings Presentation
15 slides from Brightspring Health Services's earnings presentation, Mar 6, 2025
Slide 1: Fourth Quarter 2024 Earnings Presentation
Fourth Quarter 2024 Earnings Presentation March 6, 2025 1
Slide 2: Forward-Looking Statements; Non-GAAP Financial Information
Forward-Looking Statements; Non-GAAP Financial Information Forward-Looking Statements • potential substantial malpractice or other similar claims; This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking
Slide 3: A leading pharmacy and health care provider in the U.S.
A leading pharmacy and health care provider in the U.S., serving large and growing markets that have significant unmet needs, with high-quality and integrated services that improve outcomes and reduce cost 3
Slide 4: BrightSpring at a Glance
BrightSpring at a Glance Attractive Markets, Needed Solutions ✓ Serving large and growing healthcare markets of high-cost and complex patient populations – in preferred and lower-cost home and community settings, for high ROI and patient satisfaction Focus on Growth and Operations ✓ Driving outsized
Slide 5: BrightSpring Financial Highlights
BrightSpring Financial Highlights Fourth Quarter 2024 $3,053M 28.6% $167.4M 17.4% Revenue Revenue Growth Adj. EBITDA Adj. EBITDA Growth Fourth Quarter 2024 ($ in millions) Y/Y Growth acy Solutions Pharm Pharmacy Solutions Revenue $2,397 +34.3% Hom acy ea arm nd Infusion and Specialty y Ph C 1,796 +4
Slide 6: Q4 2024 & FY 2024 Revenue and Adjusted EBITDA Results
Q4 2024 & FY 2024 Revenue and Adjusted EBITDA Results ($ in millions) Q4 2024 Revenue ($ in millions) FY 2024 Revenue $11,266 +28.6% $3,053 $8,826 +27.6% $2,512 $2,375 $656 +9.0% $2,304 $589 +11.3% Provider Services $8,754 $2,397 Pharmacy Solutions $6,522 +34.2% $1,785 +34.3% Q4 2023 Q4 2024 FY23 FY
Slide 7: Q4 2024 Pharmacy Solutions Segment Performance
Q4 2024 Pharmacy Solutions Segment Performance ($ in millions) Q4 2024 Revenue Infusion and Specialty Pharmacy Home and Community Pharmacy Pharmacy Solutions +34.3% $2,397 $601 Business Metrics $1,785 +16.5% $516 $1,796 Prescriptions dispensed 10,967 $1,270 +41.5% (thousands) +14.4% y/y 9,591 in 4Q2
Slide 8: Q4 2024 Provider Services Segment Performance
Q4 2024 Provider Services Segment Performance ($ in millions) Q4 2024 Revenue Home Health Care Community and Rehab Care Provider Services +11.3% $656 $589 Business Metrics +7.5% $376 $349 Home Health Care average 45,892 $240 +16.9% $280 +8.7% y/y daily census 42,221 in 4Q23 Q4 2023 Q4 2024 Community
Slide 9: Financial Performance: Three Months Ended December 31, 2024
Financial Performance: Three Months Ended December 31, 2024 Three Months Ended December 31, 2023 vs. Three Months Ended December 31, 2024 Pharmacy Solutions Provider Services Three Months Three Months Three Months Three Months ($ in millions, Change ($ in millions, Change Ended December Ended Decemb
Slide 10: Financial Performance: Twelve Months Ended December 31, 2024
Financial Performance: Twelve Months Ended December 31, 2024 Twelve Months Ended December 31, 2023 vs. Twelve Months Ended December 31, 2024 Pharmacy Solutions Provider Services Twelve Months Twelve Months Twelve Months Twelve Months ($ in millions, Change ($ in millions, Change Ended December Ended
Slide 11: 2025 Guidance, Excluding Community Living
2025 Guidance, Excluding Community Living 2025 Fiscal Year Guidance Prior Updated FY 20241 FY 2025 Guidance2 FY 2025 Guidance2 ($ in millions) December 31, 2024 Provided January 20, 2025 Provided March 6, 2025 $10,050 – $10,500 $10,150 – $10,600 Pharmacy Revenue $8,754 14.8% – 19.9% y/y2 15.9% – 21.
Slide 12: De-leveraging Plan and Capital Allocation Priorities
De-leveraging Plan and Capital Allocation Priorities De-leveraging driven by operational performance and capital allocation Proforma Long-Term Pre IPO / Post-Equity and Debt Leverage Ratio Leverage Cash Flow Transactions Leverage Ratio (1) by year-end • Capex needs: 1% of revenue Ratio Target Genera
Slide 13: Appendix
Appendix 13
Slide 14: Non-GAAP Reconciliations
Non-GAAP Reconciliations For the Three Months Ended For the Twelve Months Ended ($ in thousands) December 31, 2023 December 31, 2024 December 31, 2023 December 31, 2024 Net Loss $ (7,201) $ 15,404 $ (156,835) $ (20,521) Income Tax (Benefit) Expense (7,591) 8,783 (20,578) (14,217) Interest Expense 83
Slide 15: Basic and Diluted Weighted-Average Shares Outstanding Calculation
Basic and Diluted Weighted-Average Shares Outstanding Calculation utilized in calculating Diluted EPS to Adjusted EPS For the Three Months Ended (in thousands) March 31, 2024 June 30, 2024 September 30, 2024 December 31, 2024 Pre-IPO Shares (12/31/2023) 117,857 117,857 117,857 117,857 Initial Public
BrightSpring Health Services — Q4 2024 Earnings Presentation on 6ix